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Summary
A snake venom-like protease isolated by a differential display screen between normal and osteoarthritis (OA)-affected cartilage (designated
as cSVP) has a cDNA sequence identical to tumor necrosis factor (TNF)Æ convertase enzyme (TACE) and belongs to the adamalysin group
of proteases. It has unique structural properties and when expressed in baculovirus, cleaves preferentially proTNFÆ to TNFÆ. The
OA-affected cartilage has upregulated mRNA for TNFÆ and TACE as compared to normal cartilage. TNFÆ and TACE regulate inflam-
matory mediators in OA-affected cartilage which can be inhibited by both soluble TNFÆ receptors and inhibitors of TACE. These experi-
ments demonstrate a functional paracrine/autocrine role of TNFÆ in OA-affected cartilage that is modulated by upregulated levels of
chondrocyte-derived TACE.
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Studies in animal models of arthritis indicate that tumor
necrosis factor (TNF)Æ may be a pivotal cytokine involved
in the disease process. Injection of anti-TNF-Æ Abs1
or soluble TNF-ÆR2 has proven to be highly effective in
reducing clinical score, paw swelling, and histologic
severity of the disease. Extension of these studies in
patients with rheumatoid arthritis in phase II and III clinical
trials has yielded very encouraging results.
Recently studies have demonstrated that hydroxamate
inhibitors of MMPs specifically inhibit the release of
membrane proTNF-Æ from various cell surfaces, including
rheumatoid arthritis synovial cell cultures. These inhibitors
of proTNF-Æ processing could protect mice against a
lethal dose of endotoxin administered to them.3 TNF-Æ
convertase (TACE) was isolated using these inhibitors as
ligands by affinity purification or differential display of
gene expression in normal and arthritis-affected cartilage.
TACE could cleave the Gln-Ala-fl -Val-Arg sequence of
wild type proTNF-Æ but not a mutant non-cleavable
proTNF-Æ in vitro. These studies identify another target
which may attenuate the activity of soluble TNF-Æ in
various diseases. Although the role of TNF-Æ in the
pathogenesis of RA is well defined, it has not been
investigated in depth in OA. However, (a) Synovial fibro-
blasts from OA-affected joints show upregulation of TNF-Æ
and TNF-Æ receptors; (b) Focal loss of cartilage in OA- is
associated with overexpression of p55 TNF-Æ receptors;
(c) OA-affected cartilage is more susceptible to the effects
of TNF-Æ as compared to normal cartilage. In view of
these observations, we investigated the role of TNF-Æ and
TACE in human OA-affected cartilage.392Methods
The isolation, and characterization of TACE was per-
formed as recently reported.4 RNA extraction from articular
cartilage, PCR analysis, Northern blot analysis OA-organ
cultures, and sequence analysis have been described in
4,5Address correspondence to: A. R. Amin, Hospital for Joint
Diseases, 301 East 17th Street, Room 1600, New York, NY 10003.Results
We have standardized a method to isolate MMPs from
matrixins and adamalysin that are differentially expressed
in OA-affected cartilage.4 This study lead to the identifi-
cation of TACE. The full length cDNA sequence shows
three striking features:
(a) an unusually long prodomain (as compared to
matrixins);
(b) a catalytic region of this enzyme (similar to that seen
with the snake venom proteases) which spans
the region between the cysteine switch and the
zinc binding region is distinct from that seen in the
matrixins;6
(c) a cytoplasmic region, like the prodomain, does not
show any significant similarity to any peptide, whose
functions are known.
A computer-generated 3-D ribbon structure based on the
amino acid sequence and co-crystallized catalytic domain
of TACE with a protease inhibitor, hydroxamic acid resolved
at 2.0 A were similar.4,7 This active site cleft of TACE
shares properties with MMPs but exhibits unique features
such as a deep pocket, merging the groove below the
surface. TACE has five stranded pleated sheets flanked by
two helixes. There are multiple (spur like) turn loops and a
long intermediate Æ-helix. The disintegrin/cysteine-rich
domain showed a structure similar to TNF-Æ receptors.
Recent studies by McKie et al.8 have also demonstrated
by in-situ immunostaining in arthritis affected cartilage.
Osteoarthritis and Cartilage Vol. 7 No. 4 393mRNA expression for other related ADAMs which include:
ADAM-10, -12 and -15 in chondrocytes. TACE mRNA is
widely distributed and the baculovirus expressed protein
cleaves native proTNF-Æ and TNF-Æ specific peptides.
TACE and TNF-Æ mRNA are upregulated in arthritis-
affected cartilage and not normal cartilage (Fig. 1).
OA-affected (but not normal) cartilage explants (which
shows elevated NOS, COX-2 and IL-1â mRNA), when
incubated in ex-vivo condition, spontaneously release nitric
oxide, PGE2 and IL-1â in quantities sufficient to cause
cartilage damage.9 We could detect TNF-Æ (1–15 pg/ml per
100 mg cartilage, 48 h, N=6) which is regulated by IL-8
production in the OA-cartilage explants. Treatment of
OA-affected cartilage explants with TNF-ÆR:Fc significantly
inhibited the spontaneous secretion of IL-8 (Fig. 2). Fur-
thermore, soluble IL-1R acted synergistically (but not
alone) with TNF-ÆR:Fc to markedly inhibit IL-8 release (Fig.
2). Thus, chondrocyte-derived TNF-Æ, like IL-1â,5 acts in
paracrine/autocrine fashion to modulate human cartilage
function.
We tested the effect of TACE inhibitors on the functions
of TNF-Æ in cartilage. Ten ìg/ml BB-16 and anti-TCN (like
TNF-ÆR:Fc) inhibited the spontaneous release of IL-8 from
arthritis-affected cartilage by ~ 80% within 72 h in ex-vivo
conditions. These experiments suggest that human
arthritis-affected cartilage has TACE activity which is
responsible for the production of functional TNF-Æ.Discussion
Our studies, for the first time, demonstrate the presence
of functional TNF-Æ and TACE in human OA-affected
cartilage not observed in normal cartilage. TACE which isconstitutively expressed in most tissues4 is upregulated in
human OA-affected cartilage. This leads to increased
TNF-Æ production. Significant amounts of TNF-Æ are not
detected in human OA cartilage explants as compared to
other inflammatory mediators9 as it may be entrapped in
the cartilage but it is functionally active. These experiments
suggests TNF-Æ (which is regulated by TACE) may have a
provokal role in the pathogenesis of OA.Addendum
Melchion et al. (1998) have shown the presence of TNFÆ
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Fig. 1. Expression of cSVP, TNF-Æ and â-actin mRNA in normal
and OA/RA-affected cartilage. Normal or OA/RA-affected cartilage
from different individuals was taken and total RNA was extracted
immediately upon receiving the samples without releasing the
cells. Equal amounts (100 ng) of total RNA were subjected to
RT-PCR analysis (30–35 cycles) using specific cSVP and TNF-Æ
primers, which generated ~ 900 bp and ~ 700 bp fragments,
respectively. The same RNA preparation (100 ng) was also sub-
jected to RT-PCR analysis of â-actin which generated a 475 bp
fragment. 100 ng of total RNA from THP-1 cells unstimulated and
stimulated with LPS were used as positive and negative controls.
In this experiment, RT-PCR analysis of RNA from OA patient No. 3
was carried out without the reverse transcriptase enzyme (RT:Con-
trol), thus indicating the lack of potential DNA contamination.
+Control designates amplification of signals from standard cSVP,
TNF-Æ and â-actin cDNA. STD designates mw standards.
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Fig. 2. Downregulation of endogenous TNF-Æ±IL-1â in
OA-affected cartilage leads to a decreased release of IL-8 in
ex-vivo conditions. OA-affected cartilage was set up in organ
culture. 10 ìg/ml of human soluble recombinant type I IL-1 recep-
tor (IL-1R) and TNF-ÆR:Fc [human TNF-Æ receptor (p80) linked to
the Fc portion of human IgG1] were added to the OA organ culture.
The specific activity of IL-1R and TNF-ÆR:Fc was 3.9×104 U/mg
and 1.2×106 U/mg, respectively. The cultures were harvested after
48 h and the IL-8 levels were examined by ELISA. ‘Control’
designates spontaneous release of IL-8 in ex-vivo conditions. Data
are expressed as ng/ml of IL-8 released by 100 mg of cartilage
(wet weight)±SD (N=3). The P values are as follows: between
control and a<0.12; between control and b<0.015; between control
and c<0.0015.References
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